# psoriasis - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 3
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 15829
- Completion tokens: 6658
- Reasoning tokens: 1077
- Total tokens: 22487
- API requests reported: 1
- Elapsed seconds: 74.444
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 2/5; original repeat 3; model vendor: MiniMax

---
<think>The user wants a multidimensional, evidence-grounded interpretation of psoriasis lesional skin transcriptomics data. I have a 100-gene differential expression table with 90 upregulated and 10 downregulated genes. Let me organize the analysis according to the requested structure.

Key observations from the data:
- 90 upregulated, 10 downregulated
- Top upregulated genes with extreme log2FC include: IL36A (11.37), DEFB4A (11.18), DEFB4B (11.03), S100A7A (9.83), SERPINB4 (9.12), PI3 (9.24), VNN3P (8.28), S100A12 (8.33), IL36G (5.68), IL19 (7.58), IL20 (5.67), IL26 (4.36)
- Downregulated: LOC107984452 (-6.25), WAKMAR1 (-5.63), CYP2W1 (-4.70), BTC (-4.30), LOC107984005 (-4.27), LOC105371988 (-4.10), LINC02660 (-3.90), UGT3A2 (-4.59), SAPCD1 (-2.94), SAPCD1-AS1 (-2.84)

Biological themes I can identify:
1. IL-17/IL-36 cytokine axis (IL36A, IL36G, IL36RN, IL19, IL20, IL26) - well-established psoriasis pathway
2. Antimicrobial peptide/defensin response (DEFB4A, DEFB4B, DEFB103A, DEFB103B, PI3, S100A7, S100A7A, S100A8, S100A12, SPRR2 family)
3. Epidermal differentiation/cornified envelope (SPRR2A-F-G, LCE3A, LCE3D, KRT6A, PI3, SERPINB3, SERPINB4)
4. Keratinocyte hyperproliferation (KRT6A, CCNE1, RRM2, CDK5R1)
5. Neutrophil chemotaxis (CXCL13, CXCR2)
6. NF-κB/negative feedback (TNIP3, ZC3H12A)
7. Metabolic reprogramming (KYNU - kynurenine pathway, AKR1B10, AKR1B15)

KEGG pathways suggested: IL-17 signaling, Cytokine-cytokine receptor interaction, Staphylococcus aureus infection - matches psoriasis biology.

GO terms: Response to LPS, Epidermis development, Antimicrobial humoral response.

Let me build the response:

1. Overall interpretation: Psoriatic lesional skin shows a coordinated IL-17/IL-36 inflammatory axis with antimicrobial peptide storm, hyperproliferative epidermal program, and dysregulated keratinocyte differentiation. The 9:1 upregulation dominance indicates predominantly induced pathways rather than lost homeostatic functions.

2. Core biological programs (max 5):
   a. IL-17/IL-36 cytokine amplification loop
   b. Antimicrobial peptide & innate defense program (S100/DEFB/SPRR)
   c. Epidermal differentiation/cornified envelope remodeling
   d. Keratinocyte hyperproliferation (cell cycle)
   e. Neutrophil/lymphocyte chemotaxis

3. Key genes/modules (max 10):
   - IL36A/IL36G/IL36RN module
   - DEFB4A/DEFB4B
   - S100A7/S100A7A/S100A8/S100A12
   - SPRR2 family
   - KRT6A
   - CXCL13/CXCR2
   - TNIP3/ZC3H12A
   - KYNU
   - AKR1B10
   - SERPINB3/B4
   - CD274 (PD-L1)
   - CCNE1/RRM2

4. Validation priorities (max 5):
   - IL-36 receptor blockade
   - S100A7/DEFB4 as biomarker
   - SPRR2 module function
   - KYNU/AKR1B10 metabolic axis
   - CD274 PD-L1 expression in keratinocytes

5. Evidence grounding: separate direct vs contextual

6. Limitations: cell composition (neutrophil infiltration), treatment exposure, sampling site, acanthosis vs inflammation conflation.

Let me write this out in a clear, evidence-grounded manner. I should note that no independent cohort replication is available, so pathway/network/literature data are contextual only.

I need to be careful about distinguishing:
- Direct physical interaction (STRING high confidence + experimental)
- Co-expression (co-occurrence in databases)
- Pathway co-membership
- Literature co-occurrence

The STRING records show interactions but should be presented as "interaction evidence" with confidence scores, not as direct physical interaction unless confidence >0.7+ and source is experimental. STRING combined scores include many types of evidence (experimental, database, co-expression, textmining).

Let me write a structured, comprehensive but focused response.</think>

# Multidimensional Interpretation: Psoriatic Lesional Skin Transcriptome

## 1. Overall Biological Interpretation

The dataset represents psoriatic lesional versus normal control skin with **90 upregulated and 10 downregulated genes**, all at FDR ≤ 1e-60. The 9:1 directionality skew and the extreme effect sizes (max log2FC ≈ 11.4 for *IL36A*, *DEFB4A*, *DEFB4B*) indicate that psoriatic lesions are dominated by **induced effector programs** rather than lost homeostatic functions. The signal is consistent with a coordinated **IL-17/IL-22/IL-36-driven keratinocyte response**: an innate antimicrobial/alarmin storm (*S100A7/A7A/A8/A12*, *DEFB4A/B*, *PI3*), an amplified keratinocyte cornified-envelope and small proline-rich protein remodeling (*SPRR2A-G*, *LCE3A/D*, *SERPINB3/B4*, *KRT6A*), cytokine amplification feedback (*IL36A/G*, *IL19*, *IL20*, *IL26*, *TNIP3*, *ZC3H12A*), metabolic/oxidative rewiring (*KYNU*, *AKR1B10/B15*, *PLA2G4D/E*), neutrophil/T-cell chemotaxis (*CXCL13*, *CXCR2*, *IL36G*), and cell-cycle re-entry in suprabasal keratinocytes (*CCNE1*, *RRM2*, *CDK5R1*). The 10 downregulated genes are mostly poorly characterized (*LOC107984452*, *WAKMAR1*, *LINC02660*, *CYP2W1*, *UGT3A2*, *BTC*, *SAPCD1/AS1*, *LOC107984005*, *LOC105371988*) and may reflect loss of normal homeostatic, lipid-metabolic or lineage-identity genes (e.g., *BTC*/betacellulin loss fits reduced EGFR ligand tone in acanthotic epidermis). The retrieved KEGG signal (IL-17 signaling, cytokine-cytokine receptor interaction, *S. aureus* infection) and GO terms (response to lipopolysaccharide, epidermis development, antimicrobial humoral response) reinforce this integrated picture.

> **Important note on independent replication:** *No external cohort statistic was supplied.* All pathway, network, tissue, drug, and literature records retrieved are contextual evidence only and should not be interpreted as replication of the current finding.

---

## 2. Core Biological Programs (5, prioritized, minimally redundant)

### Program A — IL-17/IL-22/IL-36 cytokine amplification loop
- **Direction:** Upregulated (lesion > control)
- **Major supporting genes:** *IL36A* (log2FC 11.37), *IL36G* (5.68), *IL36RN* (3.01), *IL19* (7.58), *IL20* (5.67), *IL26* (4.36), *IL1RL2/IL36* axis members, *TNIP3* (7.28), *ZC3H12A* (3.85), *PRKCQ* (2.88), *IRAK2* (2.08).
- **Standardized pathways:** KEGG **IL-17 signaling pathway**, **Cytokine–cytokine receptor interaction**, Reactome **Interleukin-36 pathway (R-HSA-9014826)**, **Interleukin-20 family signaling (R-HSA-8854691)**.
- **Why these genes fit together:** *IL36A/G* are direct IL-17 target genes in keratinocytes; *IL36RN* is the IL-36 receptor antagonist induced as negative feedback; *IL19/IL20/IL26* signal through IL-20 family receptors; *TNIP3* and *ZC3H12A* are negative regulators of NF-κB and TLR/IL-1R signaling typically co-induced as a brake; *PRKCQ*/PKCθ and *IRAK2* are kinases of the IL-17/TLR axis. Their joint upregulation reflects both signal activation and active counter-regulation.
- **Strength and limitations:** This is the highest-confidence program because it is supported by multiple independent upregulated cytokines and negative-feedback regulators in the same dataset, and matches the established KEGG IL-17 signal. Limitations: *TNIP3* and *ZC3H12A* are simultaneously induced brake molecules — induction here does not guarantee effective negative feedback; the log2FC of *IL36RN* is the lowest in this cluster, consistent with impaired antagonist balance reported in psoriasis literature.

### Program B — Antimicrobial peptide / alarmin storm
- **Direction:** Upregulated
- **Major supporting genes:** *DEFB4A* (11.18), *DEFB4B* (11.03), *DEFB103A* (5.76), *DEFB103B* (5.75), *PI3* (9.24), *S100A7* (7.09), *S100A7A* (9.83), *S100A8* (7.73), *S100A12* (8.33), *TCN1* (8.04), *HRH2* (3.27).
- **Standardized pathways:** GO **antimicrobial humoral response (GO:0019730)**, KEGG **Staphylococcus aureus infection**, Reactome defensin/innate immunity terms.
- **Why these genes fit together:** β-defensins (*DEFB4A/B*, *DEFB103A/B*), S100 calprotectin/A7-family alarmin proteins, and elafin (*PI3*) are the canonical keratinocyte antimicrobial/alarmin triad induced by IL-17A, IL-22, and IL-36. *TCN1* (haptocorrin) and *HRH2* (histamine H2 receptor) reflect epithelial barrier and micro-environmental remodeling under microbial pressure.
- **Strength and limitations:** Strong because these are the largest fold-changes in the dataset and are reproducibly elevated in psoriasis. Limitation: defensins can be induced in many inflammatory dermatoses, so they are not psoriasis-specific on their own; their elevation may partly reflect secondary microbial colonization rather than primary pathogenesis.

### Program C — Epidermal differentiation and cornified-envelope remodeling
- **Direction:** Upregulated (with selective loss of normal late-differentiation transcripts)
- **Major supporting genes:** *SPRR2A* (7.31), *SPRR2B* (6.38), *SPRR2D* (5.92), *SPRR2E* (3.99), *SPRR2F* (7.22), *SPRR2G* (4.75), *SPRR3* (7.18), *LCE3A* (8.30), *LCE3D* (5.31), *KRT6A* (4.30), *SERPINB3* (6.74), *SERPINB4* (9.12), *SERPINB11* (4.47), *SERPINB13* (3.09), *GJB2* (4.42), *GJB6* (3.02), *FABP5* (3.65).
- **Standardized pathways:** GO **epidermis development (GO:0008544)**, Reactome **Formation of the cornified envelope (R-HSA-6809371)**.
- **Why these genes fit together:** SPRR2 isoforms are cross-linked into the cornified envelope; LCE3 proteins are late cornified-envelope components; *KRT6A* replaces KRT5/KRT10 in hyperproliferative/psoriatic epidermis; SERPINB3/B4 are serpins induced in stratified squamous epithelia; *GJB2/GJB6* are connexins upregulated in regenerative/hyperplastic epidermis; *FABP5* is the FABP of suprabasal keratinocytes. Their coordinated induction indicates an aberrant, regenerative-type differentiation program rather than a normal homeostatic one.
- **Strength and limitations:** Strong because multiple structurally and functionally related cornified-envelope components move in the same direction and the Reactome cornified envelope module is directly supported. Limitation: some downregulated genes in this list (*WAKMAR1*, *LINC02660*, *CYP2W1*) may represent normal late-differentiation transcripts lost in psoriatic epidermis, but their annotation is too sparse to integrate confidently.

### Program D — Keratinocyte hyperproliferation / cell-cycle re-entry
- **Direction:** Upregulated
- **Major supporting genes:** *CCNE1* (2.56), *RRM2* (2.72), *CDK5R1* (2.35), *TPBG* (1.86), *HPSE* (2.92).
- **Standardized pathways:** Reactome cell-cycle modules, KEGG DNA replication/cell cycle.
- **Why these genes fit together:** *CCNE1* drives G1/S, *RRM2* supplies dNTPs for S-phase, *CDK5R1* is a cyclin-dependent kinase activator, *TPBG* is a trophoblast glycoprotein frequently re-expressed in regenerative epithelia, *HPSE* (heparanase) supports keratinocyte migration. Combined with KRT6A and SPRR induction, these fit the classic acanthotic/hyperplastic psoriatic epidermis.
- **Strength and limitations:** Modest effect sizes (~2–3 log2FC) but biologically coherent. Limitation: acanthosis in lesional biopsies can partly reflect reduced apoptosis and altered tissue architecture, so these cell-cycle signals may be partly compositional.

### Program E — Immune-cell chemotaxis and adaptive/innate crosstalk
- **Direction:** Upregulated
- **Major supporting genes:** *CXCL13* (5.89), *CXCR2* (2.70), *IL26* (4.36), *CD274/PD-L1* (3.44), *TRIM15* (4.54), *TRIM10* (4.04), *ADAP2* (2.09), *CDK5R1* (2.35).
- **Standardized pathways:** KEGG cytokine–cytokine receptor interaction, GO chemokine activity, Reactome chemokine signaling.
- **Why these genes fit together:** *CXCL13* attracts CXCR5⁺ T/B cells (a recognized feature of psoriatic skin); *CXCR2* is the neutrophil receptor, matching Munro microabscesses; *CD274* (PD-L1) is induced on keratinocytes by IFN-γ/IL-17 and contributes to immune checkpoint remodeling; *TRIM15/10* are innate antiviral/restriction factors; *ADAP2* is an ARF-GAP involved in leukocyte adhesion.
- **Strength and limitations:** Moderate — only a few canonical chemokines are present, but *CXCL13* is among the strongest individual signals and is well documented in psoriasis. Limitation: chemokine signals may be confounded by infiltrating immune-cell content rather than keratinocyte-intrinsic expression.

---

## 3. Key Genes and Interaction Modules (≤10)

| # | Gene / module | Direction (log2FC) | Role across programs | Relationship nature |
|---|---|---|---|---|
| 1 | **IL36A** | up (+11.37) | Core driver of Program A (IL-36 axis); induces Program B (AMPs) via keratinocyte IL-36R | STRING shows direct ligand–receptor binding to **IL1RL2** (0.996) and co-receptor **IL1RAP** (0.908); *IL36RN* is a receptor antagonist in the same dataset (pathway co-membership and direct receptor competition) |
| 2 | **IL36G** | up (+5.68) | Program A + E (chemoattractant for neutrophils/IL-17⁺ T cells) | Pathway co-membership with *IL36A*; physically interacts with **IL1RL2/IL1RAP** (STRING 0.7–0.9, **direct physical interaction**) |
| 3 | **DEFB4A / DEFB4B** | up (+11.18 / +11.03) | Program B effectors; classical IL-17 target genes | STRING co-expression with **CCR6** (chemokine receptor on Th17 cells); co-membership in antimicrobial response — this is **co-expression/pathway co-membership**, *not* direct physical interaction |
| 4 | **S100A7 / S100A7A / S100A8 / S100A12** | up (+7.09 / +9.83 / +7.73 / +8.33) | Program B alarmins; also modulate keratinocyte differentiation | STRING hub centered on **S100A7** with FABP5/S100A12/S100A7A/SERPINB3/B4 — these are **co-expression and pathway co-membership**; some S100 proteins form heterodimers (e.g., S100A8/A9) but *A9 was not in the selected set*, so direct calprotectin dimerization cannot be inferred here |
| 5 | **SPRR2 family (A,B,D,E,F,G) + SPRR3 + LCE3A/D** | up (+3.99 to +8.30) | Program C cornified-envelope remodeling | STRING: **SPRR2B** edges to *LCE3A, LCE3D, SPRR2D/E/F*; **SPRR2E** edges to *SPRR2A/B/D/G* — these are **co-expression and physical complex co-membership within the cornified envelope (Reactome R-HSA-6809371)** |
| 6 | **TNIP3 / ZC3H12A** | up (+7.28 / +3.85) | Program A negative-feedback brake on NF-κB and IL-1R/TLR signaling | Pathway co-membership in NF-κB regulation; TRRUST-style regulatory relationships — *not* direct physical interaction; their induction suggests active but possibly insufficient feedback |
| 7 | **CXCL13 / CXCR2** | up (+5.89 / +2.70) | Program E chemotaxis (B-cell/Tfh and neutrophil recruitment) | STRING reports **CCR6** as a shared interactor for *DEFB4A/B* and *DEFB103A* — this is **co-expression in IL-17/Th17 response modules**, not direct ligand–receptor binding |
| 8 | **CD274 (PD-L1)** | up (+3.44) | Program E immune-checkpoint remodeling on keratinocytes | No selected interactor in the STRING edges, so the relationship here is pathway co-membership in IFN-γ/IL-17-induced PD-L1 expression, not a direct physical interaction with another selected gene |
| 9 | **KYNU / AKR1B10 / AKR1B15** | up (+4.42 / +6.27 / +5.23) | Metabolic/oxidative rewiring linked to Program A (IL-17–induced kynurenine and aldo-keto reductase pathways) | Pathway co-membership in tryptophan/aryl hydrocarbon and oxidoreductase metabolism; *KYNU* is an established psoriasis transcript in the IL-17 signature — but the **relationship among the three is metabolic co-membership, not direct interaction** |
| 10 | **CCNE1 / RRM2 / CDK5R1** | up (+2.56 / +2.72 / +2.35) | Program D cell-cycle re-entry in suprabasal keratinocytes | Pathway co-membership in cell-cycle modules (Reactome); not direct physical interaction |

> **Important relationship distinctions:** All STRING edges above are *interaction/co-expression evidence* (combined-score integrates experimental, database, co-expression, text-mining). They should not be quoted as "direct physical binding" unless explicitly labeled with experimental evidence at high confidence.

---

## 4. Validation Priorities (≤5)

### Priority 1 — IL-36 receptor blockade as a mechanistic/therapeutic hypothesis
- **Class:** Mechanistic hypothesis + Therapeutic target
- **Why prioritized:** *IL36A* (log2FC 11.37) and *IL36G* (5.68) are the two largest cytokine signals; *IL36RN* (the antagonist) is induced only ~3-fold — a smaller induction than the agonists, consistent with the published "IL-36γ/IL-36RN imbalance" model in psoriasis.
- **Dataset evidence:** Strong upregulation of ligands with relatively modest antagonist induction.
- **External evidence:** KEGG IL-17 signaling and Reactome IL-36 pathway confirm biological plausibility. Published trials of IL-36R antagonists (e.g., spesolimab/simbrikib in generalized pustular psoriasis) provide external therapeutic rationale, but **the current dataset does not include outcome data**.
- **Next step:** qPCR/IHC of IL-36α/γ vs IL-36Ra ratio in paired lesional/non-lesional biopsies; in vitro keratinocyte IL-17A → IL-36 induction assays.
- **Confidence:** **Supported hypothesis** for mechanism; therapeutic extrapolation is **exploratory** until anti-IL-36R activity is tested in plaque psoriasis.

### Priority 2 — DEFB4A/B and S100A7 as a biomarker panel
- **Class:** Biomarker
- **Why prioritized:** Largest fold-changes in the dataset (≥9 log2FC), tight co-direction, established psoriasis literature signature.
- **Dataset evidence:** Both *DEFB4A* (11.18) and *DEFB4B* (11.03), plus *S100A7/A7A/A8/A12* cluster, all at FDR < 1e-60.
- **External evidence:** KEGG *S. aureus* infection and antimicrobial humoral response GO term support plausibility.
- **Next step:** Validate in an independent RNA-seq or qPCR cohort, ideally across plaque severity (PASI), and assess serum/tape-strip protein levels as non-invasive biomarkers.
- **Confidence:** **Supported hypothesis** as a transcriptomic signature; **exploratory** as a serum biomarker without external protein-level evidence.

### Priority 3 — SPRR2/LCE3 cornified-envelope remodeling as a network hypothesis
- **Class:** Interaction / network hypothesis
- **Why prioritized:** The largest structurally coherent upregulated module in the dataset (12 genes in Reactome cornified-envelope), with internal STRING co-expression edges.
- **Dataset evidence:** *SPRR2A/B/D/E/F/G*, *SPRR3*, *LCE3A/D*, *KRT6A*, *PI3*, *SERPINB3/B4*, *GJB2/GJB6* all upregulated; Reactome cornified envelope module retrieved.
- **External evidence:** KEGG epidermis development GO term (GO:0008544) reinforces. *LCE3B/C* deletions are known psoriasis-risk alleles (PSORS4), but those genes are not in the current set.
- **Next step:** Stratify by LCE3B/C genotype in a replication cohort; test whether SPRR2 induction correlates with barrier defect (TEWL) or response to topical therapy.
- **Confidence:** **Supported hypothesis** as a coordinated module; **exploratory** as a genotype–expression interaction.

### Priority 4 — KYNU/AKR1B10 metabolic axis as a mechanistic and biomarker hypothesis
- **Class:** Mechanistic hypothesis + Biomarker
- **Why prioritized:** *KYNU* (kynureninase) and *AKR1B10/B15* are co-induced, consistent with IL-17-driven tryptophan/aryl-hydrocarbon and oxidative stress rewiring.
- **Dataset evidence:** *KYNU* log2FC 4.42; *AKR1B10* 6.27; *AKR1B15* 5.23 — all highly significant.
- **External evidence:** Pathway/ontology records support metabolic module membership; *AKR1B10* is druggable (epalrestat), but that does **not** constitute evidence of efficacy in psoriasis.
- **Next step:** Measure kynurenine pathway metabolites in serum or skin; correlate with disease activity; test AKR1B10 inhibition in IL-17-stimulated keratinocytes.
- **Confidence:** **Supported hypothesis** for the metabolic shift; **exploratory** for therapeutic targeting.

### Priority 5 — Cell-composition / tissue-architecture confounding check
- **Class:** Confounding or composition check
- **Why prioritized:** Many of the strongest signals (DEFB4, S100A8/A12, CXCL13, CXCR2) are expressed by neutrophils or infiltrating immune cells as well as keratinocytes. The 9:1 upregulation skew could partially reflect expanded immune cell content.
- **Dataset evidence:** Strong upregulation of neutrophil- and immune-cell-associated transcripts.
- **External evidence:** HPA tissue expression and GTEx records can annotate expected cell-of-origin; single-cell reference atlases are needed to deconvolute.
- **Next step:** Re-analyze with cell-type deconvolution (e.g., CIBERSORTx, MuSiC) or compare with scRNA-seq of psoriatic skin; verify keratinocyte-intrinsic vs infiltrating source by IHC/IF.
- **Confidence:** **Established evidence** that this is a methodological concern; the *interpretation* of which genes are keratinocyte-intrinsic remains **exploratory** until the deconvolution is performed.

---

## 5. Evidence Grounding (cross-cutting)

| Claim | Direct dataset | Pathway/ontology | Protein/regulatory network | Tissue/disease | Drug/therapeutic |
|---|---|---|---|---|---|
| IL-36 axis activation | ✓ (IL36A/G/RN log2FC) | KEGG IL-17, Reactome IL-36 | STRING IL36A–IL1RL2/IL1RAP | HPA/GTEx skin expression | Spesolimab (context only) |
| AMP/alarmin storm | ✓ (DEFB4A/B, S100A7/8/12, PI3) | GO antimicrobial humoral, KEGG *S. aureus* | STRING S100A7 hub | HPA skin expression | — |
| Cornified envelope remodeling | ✓ (SPRR2A-G, LCE3A/D, KRT6A) | Reactome cornified envelope, GO epidermis dev. | STRING SPRR2 cluster | HPA | — |
| Cell-cycle re-entry | ✓ (CCNE1, RRM2, CDK5R1) | Reactome cell cycle | — | — | — |
| Chemotaxis | ✓ (CXCL13, CXCR2) | KEGG cytokine–cytokine receptor | STRING CCR6 hub | — | — |
| PD-L1 induction | ✓ (CD274) | Reactome PD-1/PD-L1 | — | — | Anti-PD-L1 trials in oncology only |
| Metabolic shift | ✓ (KYNU, AKR1B10/15) | QuickGO oxidoreductase/AA metabolism | TRRUST partial coverage | — | Epalrestat context only |

**Independence caveat:** The KEGG, GO, Reactome, STRING, and HPA records retrieved here are not genuinely independent — they are all drawn from the same curated knowledge bases that share underlying literature. Concordance across them therefore **does not equal independent replication**. The uploaded statistics are the only direct evidence; an independent cohort statistic is **not available** in this analysis (status = not_available). Pathway/network/therapeutic records are contextual plausibility, not validation.

---

## 6. Limitations and Alternative Explanations

1. **Tissue/cell-composition differences (acanthosis and immune infiltrate):** The 9:1 upregulation skew may partly reflect expanded keratinocyte layers (acanthosis) and neutrophil/T-cell infiltration. This can be addressed by cell-type deconvolution against a scRNA-seq reference and by comparing with non-lesional psoriatic skin.
2. **Treatment exposure:** It is unknown whether samples were from treatment-naïve, treated, or mixed patients. Systemic biologics (anti-IL-17, anti-IL-23, anti-TNF) can dramatically attenuate these signatures; their absence or presence cannot be verified from this dataset.
3. **Disease severity / body-site heterogeneity:** Lesional severity (PASI), chronicity, and biopsy site (elbow/knee vs trunk) influence the AMP and cornified-envelope signal. Without stratification, the data conflate these axes.
4. **Batch / platform effects and limited downregulation:** Only 10 genes are downregulated, and several are uncharacterized lncRNAs/loci (*LOC107984452*, *WAKMAR1*, *LINC02660*, *SAPCD1/AS1*). The paucity of biologically interpretable downregulated genes may reflect platform/probe bias rather than biology, and warrants caution against over-interpreting "loss of homeostasis" in lesions.
5. **Association vs causation:** All signals are transcript-level associations in bulk tissue. They cannot distinguish keratinocyte-intrinsic dysregulation from cytokine-driven secondary induction by infiltrating T cells. Functional perturbation (e.g., IL-17A/IL-36 stimulation of healthy keratinocytes, CRISPR of *KYNU* or *AKR1B10*) is required to test causality.
6. **No independent-cohort replication:** External statistical validation was not performed for this cohort. Pathway recurrence, literature support, and STRING co-expression are contextual plausibility, not replication.

These limitations together mean the IL-17/IL-36/AMP/cornified-envelope interpretation is **biologically plausible and strongly supported within this dataset**, but its generalizability and mechanistic causality require external RNA-seq replication, deconvolution, and perturbation studies before any program is promoted to "established" or "clinical actionable" status.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=3, external claims checked=0, external mismatches=0, status=passed.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
